AID (APS) book now available in French!

Thanks to the dedicated efforts of Olivier Legendre and Dr. Mihaela Muresan, my book “Automated Insulin Delivery: How artificial pancreas “closed loop” systems can aid you in living with diabetes” (available on Amazon in Kindle, paperback, and hardcover formats, or free to read online and download at ArtificialPancreasBook.com) is now available in French!

The French version is also available for free download as a PDF at ArtificialPancreasBook.com or in Kindle (FR), paperback (FR), and hardcover (FR) formats!

 

French version of the AID book is now available, also in hardcover, paperback, and Kindle formats on Amazon

Merci au Dr. Mihaela Muresan et Olivier Legendre pour la traduction de l’intégralité de ce livre !

(Thank you to Dr. Mihaela Muresan and Olivier Legendre for translating this entire book!)

An example of the challenges of (constantly) titrating pancreatic enzyme replacement therapy (PERT)

As someone new to EPI who is also new to figuring out how to optimally dose my pancreatic enzyme replacement therapy (PERT), I’m constantly balancing the cost of PERT from prescription enzymes against the cost of over the counter enzymes.

I’ve personally calculated that one pill of my current dose of PERT covers about 30-4o grams of fat, and 30 grams of protein.

Meals with more than 30 grams of protein get 2 PERT pills, but meals with more than 40 or so grams of fat could be covered by 1 PERT pill and some OTC lipase.

But not all meals come with nutrition information, which makes titrating PERT at every single meal a challenge.

And, now that I’ve realized I’m likely not sensitive to all FODMAPs after all (hooray, although I may still have some slight sensitivity to massive amounts of onion or garlic), I’ve been able to eat a lot more takeout food from restaurants, both enthralling my taste buds and challenging my brain trying to estimate how much fat and protein there is in what I am choosing to eat.

I’ve been keeping careful notes of what I’m eating along with my fat and protein estimates and the results following each meal. Then, if I want to repeat or alter a similar meal, I can use my data and results to guesstimate my next PERT dosing.

For example, we have a local taco place that has done a really good job to enable online ordering with gluten-free and celiac tags in the order, so you can order digitally without having to talk to humans at the store. A few weeks ago, I ordered 3 tacos and some queso dip. It was delicious. I estimated it was more than 30g of protein, so I took 2 PERT with it.

However, while I didn’t have post-meal immediate symptoms, my next-day results were slightly off, and I made a note that I probably needed a little more lipase the next time I had that quantity of tacos.

Yesterday, I ordered 3 tacos again but decided to try a small “street corn” appetizer instead of queso. Corn is less fat and protein than queso, but I figured there was still >30g of protein from tacos like from before, so I took 2 PERT. This time, due to my notes, I added a few lipase to cover additional fat.

I had no immediate post-meal symptoms and felt great! However, today indicated that I did not have enough enzymes, and I’m suspecting that it’s because I swapped one of my taco types. Last time, I had a shrimp taco, but this time I tried a lamb taco for my third taco type. Even with the reduced fat and protein going from queso to corn, the increase in fat and/or protein (likely the protein, given my extra lipase) from shrimp to lamb meant that my meal was not optimally dosed.A gif showing three tacos and queso plus 2 PERT got ok results, but next time I swapped queso for corn and added lipase and still got it wrong, likely due to increased fat and protein in lamb instead of shrimp in one of the tacos.

 

Next time, I need to pay closer attention to what kind of tacos I eat as well as whether I get queso or not. If I did the same meal (three tacos, one of which is lamb, and corn), I’d probably experiment with 3 PERT to cover the suspected increased protein that I was missing with the 2 PERT + extra lipase. If I went back to a shrimp taco and queso, I’d probably re-try 2 PERT + extra lipase again.

PERT dosing, like insulin dosing, involves a lot of experimentation and some art, and some science, to try to get it right (or better) every time.

(PS, if you didn’t see them, I have other posts about EPI at DIYPS.org/EPI, including one about PERT Pilot, the first iOS app for Exocrine Pancreatic Insufficiency! It’s an iOS app that allows you to record as many meals as you want, the PERT dosing and outcomes, to help you visualize and review more of your PERT dosing data!


You can also contribute to a research study and help us learn more about EPI/PEI – take this anonymous survey to share your experiences with EPI-related symptoms!

A Do-It-Yourself Protocol for Over-The-Counter Enzymes for Suspected Exocrine Pancreatic Insufficiency (EPI) Before Gaining Access to Pancreatic Enzyme Replacement Therapy (PERT)

A humorous side note – the title of this blog, DIYPS, stands for “do-it-yourself pancreas system”, the name I gave my first automated insulin delivery (AID) system, back in 2013. An AID system doesn’t fully replicate all functions of the pancreas, so we evolved from describing it as an artificial pancreas system (APS) to automated insulin delivery (AID). But now that I have exocrine pancreatic insufficiency and am doing quite a bit of DIY around titration of enzymes….the name of this blog feels more appropriate than ever.

After I started writing about exocrine pancreatic insufficiency, I’ve gotten a lot of questions from friends and connections who think they might have EPI. (And they are likely not wrong – there are estimates that as many as 40% of people with type 1 diabetes have lowered elastase levels. Alone, that doesn’t indicate EPI, but if symptomatic and you’ve already ruled out celiac and gastroparesis, it should be (in my opinion) high on the list of things to test for. Ditto for other types of diabetes and anyone with celiac disease.) Some people, though, may have delays in getting doctor’s appointments, and/or clinicians who aren’t (yet) willing to order the elastase or other EPI-related tests without testing for other things first.

This post is for that group of folks, and anyone stumbling across this post who has seen their test results for their fecal elastase testing indicating they have “moderate pancreatic insufficiency” or “severe pancreatic insufficiency” and are wondering what they can do while they wait for their doctor’s appointment.

It’s also for people with EPI who are struggling to afford their pancreatic enzyme replacement therapy (PERT) or are limiting the number or size of meals they eat as a result of the cost of PERT.

A bit of background on why I did the math about OTC enzyme cost and why I had tested them myself

Due to the holidays in December 2021 I had a lag between getting my test results (over Christmas) and then confirming that my doctor would write a prescription for PERT, and then a delay in getting it filled by the pharmacy since they had to order it. One of the things I did during that time was read up a lot about PERT and also look to see if there were any other kinds of enzymes that would be useful to take if my doctor didn’t want to prescribe me PERT. I found out that PERT contains THREE types of enzymes, and together they’re known as pancrelipase. Pancrelipase contains lipase (helps digest fat), protease (helps digest protein), and amylase (helps digest starches and other complex carbohydrates). It’s typically made from ground up pig pancreas, which is one of the reasons that PERT costs so much. Amylase from non-pancreatic sources is not widely available for human consumption, but there are some other ways to make protease and lipase. And it turns out that these standalone enzyme versions, often produced by microbes, are available to buy over the counter.

While waiting for my test to be ordered, I went ahead and ordered a standalone lipase product that is over the counter (OTC). In part, that was because some of the reviews for lipase talked about having EPI and how they were only sensitive to lipase, and so this was a viable and cheaper alternative for them rather than taking PERT with all 3 enzymes, since they didn’t need that. Based on my experience with FODMAPs and trying an enzyme powder to target fructans (which did help me some), it seemed like trying small doses of lipase would help if I did have EPI, and likely wouldn’t hurt even if I did not have EPI.

And it helped. It didn’t reduce all my symptoms, but even minor doses (3000 units of lipase) made a noticeable difference in my symptoms and I got a sense for what meals were more fat and protein-laden than others.

As a result, when my test results came in and I was on the borderline for moderate EPI, I agreed with my HCP that since it likely wouldn’t hurt to take PERT (other than the cost), and it would be obvious if it helped, that I should try PERT.

So having done the tests with OTC (over the counter) lipase was helpful for deciding to take PERT and advocating for my prescription.

And it turns out, wow yes, I do have EPI and do definitely need PERT (more about my first two weeks on PERT here).

And as I wrote here, because I had the OTC lipase sitting around, even after I finally had access to PERT, I eventually titrated my dosing and calculated separate ratios for lipase:fat and protease:protein, so I can decide for every meal or snack whether I need one full PERT (all three enzymes), two PERT, a PERT plus some lipase (and how much), or just a standalone OTC lipase. The cost differs greatly between those options: one PERT might be $9 and a standalone lipase pill around $0.26. You can’t break apart a PERT (e.g. take only half), so adding a few lipase is a cost-effective approach if you don’t need more protease or amylase and the OTC lipase works for you.

Some of the reasons to explore over the counter enzymes with exocrine pancreatic insufficiency or a suspected case of EPI

One interesting thing about one of the main tests (fecal elastase) used to assess EPI is that it is NOT impacted by taking enzymes. Someone who is started on pancreatic enzyme replacement therapy (PERT) can still have an elastase test without stopping taking PERT. So if someone had an inconclusive result or was borderline and started taking PERT, but their doctor wanted to re-test again, the use of PERT would not affect the test. The same goes for other types of enzymes.

I’ve realized that the following groups of people might want to investigate various OTC enzyme options:

  • Someone who has been diagnosed with EPI, but has done careful testing with meals of various sizes (low fat & high protein, high fat & low protein, etc.) to determine that they really only need lipase, may benefit from cheaper lipase-only OTC options.
  • Someone who has a test result for EPI but doesn’t yet have an appointment with their doctor or a prescription for PERT could start taking some OTC enzymes for quicker symptom relief, even if they ultimately want to use PERT for all their enzyme needs once they get their prescription filled.
  • Someone diagnosed with EPI who cannot afford the ideal dose of PERT that they need for their meals and snacks, may want to calculate the out of pocket costs for OTC lipase (not covered by insurance) vs the cost of PERT with or without insurance.
  • Someone who can’t get tested for EPI, but suspects they have EPI, might want to also explore OTC lipase and/or OTC multiple enzyme products.

However, not everyone with EPI will want OTC enzymes. Some people may have great insurance coverage, so their PERT costs them less than $9 a pill. OTC enzymes are not covered by insurance, but I’d still do the math and assess what your standard cost is per pill, because it may surprise you how cheap add-on OTC lipase is vs. your insurance deductible or copay to take additional PERT for larger meals. The other reason some people may not want to take OTC enzymes is the pill burden: OTC doses tend to be smaller, so you usually need to take more pills to cover the same meal as a single, larger PERT.

Picking what enzymes (in general, or specific brands) work for you

I often see a variety of OTC enzyme products recommended in peer groups on social media for EPI. There are no studies that I can find assessing the efficacy of these OTC brands (meaning, how good they are). I would be very cautious when trying different single or multiple enzyme products and keep a careful log of your symptoms from before enzymes as well as symptoms at every meal that you take enzymes, and your bathroom results afterward. This can help you assess OTC enzymes as well as PERT if you get access to it. By having a good log of your symptoms, you can tell if you’re taking enough enzymes (OTC or PERT) or if you’re developing new symptoms (which could be a side effect of whatever brand/type you are taking).

There are multiple brands and sizes of PERT, too, and it’s possible that a filler product or how the PERT is made by one brand doesn’t work well for you. If that’s the case, you can try another brand of PERT.

The same goes for OTC enzymes: it is very possible some types of pills may be made with ingredients that could bother you and cause symptoms themselves. You should definitely be very cautious if you go this route and explore small doses and ensure no side effects (no new symptoms) before increasing any doses.

When I search for lipase, it’s easy to find standalone lipase (here is an example, as an Amazon affiliate link). When I search for protease, it’s more common to find products that are multiple enzymes (e.g. lipase AND protease AND other random things that are “good for digestion”). Personally, I’m very wary of anything OTC that’s described as “digestive enzymes” with additional ingredients and prefer to stick to products that only have the ingredients I’m looking for (lipase, protease, and amylase only).

A pro-con list for over the counter (OTC) enzymes for EPI. Pros include: lower cost overall and per pill; that you can take smaller quantities of individual enzymes; and you can buy them without a prescription. Cons include: it's not covered by insurance so cost is out of pocket; you have to take more pills with smaller amounts of enzymes; it's not regulatory approved so othere are no studies on efficacy; and providers may not be able to advise for titration.

The amount of enzyme also matters

The amount of enzyme you take matters, which is probably the second place that people trip up and make mistakes when trialing over the counter (OTC) enzymes. For example, the starting dose recommended for people with EPI is 40,000-50,000 units of lipase. Some of the most common OTC pills have 4-6,000 units of lipase: that means taking 10 OR MORE PILLS per meal in order to get the starting dose. Could you do that? Absolutely. (10 x $0.26 means that is around $2.60 cost, which may still be cheaper than the prescription pills.) However, the burden of consuming that many pills is pretty high in the long run. But you might be ok with that in the short run. There are other OTC options like this one (which I do use myself) that has around ~17,000 units of lipase. They are more expensive per pill, but you have to take fewer (e.g. 3-4 pills per meal) to match the starting dose.

For a lot more info on dosing, read this post about the starting dose and how most people end up needing MORE enzyme than this amount. Then read this post about how to figure out how much enzymes you may need to adjust to the food you’re eating and end up with an optimal dose. (You can also use PERT Pilot to help you with that).

That’s an advanced step, though, so if you’re just getting started I would focus on getting the minimum starting dose (equivalent to 40-50,000 units of lipase per meal) and see how that goes, then titrate (increase) from there.

In diabetes, we often say “your diabetes may vary” (YDMV), indicating that different people can have different experiences.

In EPI, it’s no different – “your digestion may vary” and it’s important to test and record and find what works for you, and to find a balance of reducing or eliminating symptoms with enzymes in a cost-effective way that you can afford.

(PS, if you didn’t see them, I have other posts about EPI at DIYPS.org/EPI including one about PERT Pilot, the first iOS app for Exocrine Pancreatic Insufficiency! It’s an iOS app that allows you to record as many meals as you want, the PERT dosing and outcomes, to help you visualize and review more of your PERT dosing data!)


You can also contribute to a research study and help us learn more about EPI/PEI – take this anonymous survey to share your experiences with EPI-related symptoms!

Cost calculations of Pancreatic Enzyme Replacement Therapy (PERT) for Exocrine Pancreatic Insufficiency (EPI) and alternative over the counter enzyme products

I previously wrote about my experience figuring out that I have exocrine pancreatic insufficiency (known as EPI or PEI), and also a little bit about starting on pancreatic enzyme replacement therapy (PERT). I talked briefly about the method I was using to figure out the right amount of PERT for me, but I realize that there’s a lot more detail I could provide about how to titrate enzymes in general, and not just PERT.

Some background first, though. When I write about PERT (pancreatic enzyme replacement therapy), I am talking about the FDA-approved class of drugs (called “pancrelipase”) that contain THREE types of enzymes, which the FDA calls “pancreatic enzyme products” or PEPs. Pancrelipase contains lipase (helps digest fat), protease (helps digest protein), and amylase (helps digest starches and other complex carbohydrates). As of 2010, all pancrelipase products that are marketed for EPI must be FDA approved.

Any time I refer (here or in other blog posts) to other enzyme products (either single enzyme or multi-enzyme), I’m referring to over the counter products that are not FDA approved.

Why does FDA approval matter for PEPs? FDA approval is essentially a rubber stamp saying you can trust the FDA to have validated that the companies making these products are making them as they describe them, meaning if they say they have 25,000 units of lipase, they actually have 25,000 units of lipase in them. (And protease and amylase). FDA-approved PEPs used in PERT are made from ground up pig pancreas (really), which is why they’re expensive. There is no generic PEP or PERT. (FDA also has a nice page here explaining the importance of understanding what is and is not an approved PEP/PERT product, and it also explains the brands that are currently approved and the differences between them.) This matters because when you talk about the cost people will probably suggest a “generic” of PERT, but there isn’t one.

However, there are non-FDA-approved over the counter enzyme products. They do exist, but because they have not been vetted by the FDA, I (and you!) should be wary about trusting them when they say they contain X units of lipase or any other enzyme product. Additionally, there are no studies (that I can find) comparing the efficacy between over the counter enzymes (single or multi-enzyme products) and FDA-approved PERT. (If you have found such a study, please leave a comment!)

So does that mean you can’t take them? No, I’m not saying that. What I am saying is you should only try other products with enzymes if you are willing to carefully test and vet FOR YOURSELF whether they work FOR YOU or not. (P.S. – did I mention I’m not a doctor? This is not medical advice; for medical advice, talk with your doctor. Although, doctors may not be aware of the over the counter enzyme options either, and this post might be worth sharing with them as well).

Three goals for optimally titrating enzymes for exocrine pancreatic insufficiency

I have three goals for getting my PERT dose titrated well.

  • First, get enough enzymes (through PERT) to reduce all symptoms.
  • Second, test and assess my lipase:fat and protease:protein ratios so I can figure out how to optimally dose enzymes for new meals of different amounts of fat and protein.
  • Third, optimize for reducing cost with enzymes, through a combination of supplementing PERT with standalone lipase and/or using lipase for fat-only snacks.

Here’s an example of how you might consider vetting over the counter enzyme products, and using them to supplement your FDA-approved (and hopefully insurance-covered) PERT:

As I mentioned earlier, I titrated and found out that my current dose of PERT covers about 30-40 grams of fat and 30 grams of protein. Some individuals only need support in digesting fat (e.g., need only lipase), but I have found that my body also needs support in digesting protein. (However, I don’t appear to need much amylase for carbohydrates.) Therefore I am tracking what amount of fat and protein I am eating with every meal. A 25,000 (lipase) dose of my PERT also contains enough protease to cover 30 grams of protein. Sometimes, I eat higher (>30-40g) fat meals that mean I need more lipase. So I would need two pills of the current dose of PERT, because 25,000 only covers ~30-40g of fat (FOR ME).

But – what if there was another way to get additional lipase without needing a full second pill of PERT, if I don’t need the additional support for more protein for this meal?

Enter over the counter enzyme options. In this example, a single enzyme option for lipase. Here is an example (Amazon affiliate link) to a standalone, single enzyme lipase product that is available as an over the counter product.

I personally have experimented with using standalone over the counter lipase to supplement my PERT dose, for the reason described above (needing more lipase but not necessarily needing more protease or amylase). The reason I would choose standalone lipase has to do with cost.

PERT, being ground up pig pancreas, is expensive. There is no generic for PERT! However, there have been methods to develop lipase from microbes as well as other sources beyond animals. Thus, it is possible to have a standalone source of lipase that is a lot cheaper than PERT. How much cheaper? Well, the bottle linked above when I calculated this was $23.50 for 90 pills. One pill each contains roughly 3,150 units of lipase (again, caveat from above about trusting the amount in over the counter products). That means each pill ($23.50/90 pills) is $0.26 USD, and each 1,000 units of lipase is roughly $0.08.

This math is then helpful to compare the cost of PERT. Depending on the size of prescription PERT, you might see a prescription anywhere from 3,000 to 25,000 to 36,000 units (depending on the brand, they have different amounts, but they are all measured based on units of lipase). Using GoodRx, you can generally compare retail prices of medications, such as this search for 24,000 PERT of one brand (90 capsules) or this search for 25,000 PERT of a different brand (also 90 capsules). Both of them are in the ballpark (for 90 capsules each) of $700-900, so let’s use $800 for 90 capsules for simple math. The per-pill price is $8.89 ($800/90 pills). The per-1,000 unit of lipase cost depends on whether you are using the 24,000 PERT ($8.89/24) or 25,000 PERT ($8.89/25) option, but those are roughly $0.37 and $0.36 per 1000 units of lipase.

So if you were to consume a meal that was ~10g of fat above your current PERT dose, and you didn’t need additional protein support, it would be cheaper to add on additional lipase (at $0.08 per 1000 units of lipase) as a standalone enzyme product instead of an additional PERT (which is, per our estimates, ~$0.36 per 1000 units of lipase). You don’t get to break apart a PERT (It can’t be cut in half, for example), so the per-pill cost is the better comparison. Adding a 3000-ish unit lipase onto your meal to cover an additional 10g of fat costs $0.26, and a second PERT is $8.89.

Therefore, a meal that needs 28,000 lipase is cheaper as 1 PERT and 1 extra standalone lipase rather than 2 PERT.

This of course assumes you have tested the standalone lipase and found that it works for you. I personally have done so and found that standalone lipase of the brand I chose works for this purpose (there are many brands and sizes: again, test what works for you), so I can titrate my meals as PERT+lipase, or even take 1-2 lipase (depending on the fat content) for a snack that’s mainly fat. However, again, a caveat that I personally am sensitive to protein and am tracking everything that I’m eating, so I know my personal math very well. Typical PERT dosing and recommendations is to take “2 or more” for meals or “1-2 for snacks”, but that completely ignores how much fat and protein is in the meals, and might be significantly undertreatment or overtreatment for you.

Why does undertreatment matter? Well, you get symptoms. Those are no fun.

Why does overtreatment matter? Well, you can get constipation. (I haven’t had it, but it also doesn’t sound like fun).
A gif showing a square moving along a spectrum from "too little" to "too much enzyme". Too little enzyme and you have symptoms, not enough and you reduce but don't eliminate symptoms. Enough enzymes and you eliminate symptoms. Too much risks constipation.

My approach was making sure my meals were covered first with prescription PERT, then evaluating additional standalone products that I could use to supplement or replace PERT depending on what I was eating, so I could prioritize reducing symptoms and then for improving the cost required to achieve that.

There are other standalone enzyme products, including products containing multiple enzymes. If you join one of the Facebook groups for EPI, you’ll see people recommencing various names of enzymes for over the counter products. But again, you really should test things and see if they work for you. Read all the ingredients on any product you’re taking. A lot of times you can search for lipase and you’ll get a multiple-enzyme product. And that product may have additional ingredients or fillers that don’t sit well with you. You may even find that one brand of prescription PERT might not work for you, whereas another one does.

My suggestions include:

  • Carefully test any product, whether it’s PERT or over the counter enzymes. Keep a good log of your post-meal symptoms and next-day symptoms (e.g. bathroom results) and try different meals with different amounts of fat and protein.
  • If you have symptoms regularly with a certain amount of enzymes, it could be either that this particular brand (over the counter or even prescription PERT) does not work well for you, OR that you are not taking enough enzymes to cover your needs.
  • If in doubt, talk with your doctor. They may/not have opinions on over the counter products, especially if they haven’t had other patients reporting back what is working for them or not, since there are no studies on those particular brands (and of course, they’re not FDA approved). But with approved PERT, they should be able to give you some more input on how to increase your dose or change your prescription to adjust. Having the data on how much fat and protein you’re eating and what results you’ve been getting could help you (and them) get to a more optimal dose more quickly.

(PS, if you didn’t see them, I have other posts about EPI at DIYPS.org/EPI)

What You Should Know About Exocrine Pancreatic Insufficiency (EPI) or Pancreatic Exocrine Insufficiency (PEI)

I have a new part-time job as a pancreas, but this time, I don’t have any robot parts I can make to help.

This is a joke, because I have had type 1 diabetes for 19+ years and 7 years ago I helped make the world’s first open-source artificial pancreas, also known as an automated insulin delivery system, that we jokingly call my “robot parts” and takes care of 90+% of the work of living with type 1 diabetes. PS if you’re looking for more information, there’s a book for that, or a free 3 minute animated video explaining automated insulin delivery. 

The TL;DR of this post is that I have discovered I have a mild or moderate exocrine pancreatic insufficiency, known as EPI (or PEI, pancreatic exocrine insufficiency, depending on which order and acronym you like). There’s a treatment called pancreatic enzyme replacement therapy (PERT) which I have been trying.

It took a long time for me to get diagnosed (almost 2 years), so this post walks through my history and testing process with my gastroenterologist (GI doctor) and the importance of knowing your own body and advocating for yourself when something is wrong or not quite right.

Background

About six years after I was diagnosed with type 1 diabetes, I was doing a summer internship in Washington, D.C. (away from home) and started getting chest tightness and frequent abdominal pain. Sometimes it felt like my abdominal muscles were “knitting” into each other. Because I had type 1 diabetes, I had heard at one point that about 10% of people with type 1 also develop celiac disease. So, thankfully, it was as simple as calling my endocrinologist and scheduling testing, and getting an endoscopy and biopsy to confirm I had celiac disease. It took about 2 months, and the timing was mostly that long due to getting back to Alabama after my internship and the testing schedule of the hospital. This is relevant detail, because I later read that it takes an average of 7 years for most people to get diagnosed with celiac disease. That has been floating around in my brain now for over a decade, this awareness that GI stuff is notoriously hard to diagnose when you’re not lucky enough to have a clear idea, like I did, of an associated condition.

So, with type 1 diabetes and celiac disease, I use automated insulin delivery to get great outcomes for my diabetes and a 100% very careful gluten-free diet to manage my celiac disease, and have not had any GI problems ever since I went gluten-free.

Until January/February 2020, when I took an antibiotic (necessary for an infection I had) and started to get very minor GI side effects on day 5 of the 7-day antibiotic course. Because this antibiotic came with a huge warning about C. diff, and I really didn’t want C. diff, I discontinued the antibiotic. My infection healed successfully, but the disruption to my GI system continued. It wasn’t C. diff and didn’t match any of the C. diff symptoms, but I really lost my appetite for a month and didn’t want to eat, so I lost 10 pounds in February 2020. On the one hand, I could afford to lose the weight, but it wasn’t healthy because all I could bring myself to eat was one yogurt a day. I eventually decided to try eating some pecans to add fiber to my diet, and that fiber and change in diet helped me get back to eating more in March 2020, although I generally was eating pecans and dried cranberries (to increase my fiber intake) for breakfast and wasn’t hungry until late afternoon or early evening for another meal. So, since my body didn’t seem to want anything else, I essentially was eating two meals a day. My GI symptoms were better: not back to how they were before February 2020, but seemed manageable.

However, in July 2020, one night I woke up with incredibly painful stabbing abdominal pain and thought I would need to go to the ER. Thankfully, it resolved enough within minutes for me to go back to sleep, but that was scary. I decided to schedule an appointment with my gastroenterologist. I took in a record of my symptoms and timing and explained what was most worrisome to me (sudden stabbing pains after I ate or overnight, not seemingly associated with one particular type of food; changes in bathroom habits, like steatorrhea, but not as severe as diarrhea). He made a list of suspected things and we began testing: we checked for C. diff (nope), parasites (nope), bloodwork for inflammation (nope, so no Crohn’s or IBS or IBD), my celiac markers to make sure I wasn’t being accidentally glutened (nope: 100% gluten-free as proven by the blood work), H. pylori (nope), and did a CT scan to check for structural abnormalities (all good, again no signs of inflammation or any obvious issues).

Because all of this happened during the global COVID-19 pandemic, I was cautious about scheduling any in-person tests such as the CT scan or the last test on my list, a colonoscopy and endoscopy. I have a double family history of colon cancer, so although it was extremely unlikely, given everything else on the list was coming back as negative, it needed to be done. I waited until I was fully vaccinated (e.g. 2 weeks after 2 shots completed) to have my colonoscopy and endoscopy scheduled. The endoscopy was to check for celiac-related damage in my small intestine since I hadn’t had an endoscopy since my diagnosis with celiac over a decade ago. Thankfully, there’s no damage from celiac (I wasn’t expecting there to be any damage, but is a nice confirmation of my 100% very careful gluten free diet!), and the colonoscopy also came back clear.

Which was good, but also bad, because…SOMETHING was causing all of my symptoms and we still didn’t know what that was. The last thing on my doctor’s list was potentially small intestine bacterial overgrowth (SIBO), but the testing is notoriously non-specific, and he left it up to me as to whether I decided to treat it or not. Having run out of things to test, I decided to do a two-week course of an antibiotic to target the bacteria. It helped for about two weeks, and then my symptoms came back with a vengeance. However, I had realized in spring 2021 (after about 9 months of feeling bad) that sometimes the stabbing abdominal pain happened when I ate things with obvious onion or garlic ingredients, so January-July 2021 I had avoided onion and garlic and saw a tiny bit of improvement (but nowhere near my old normal). Because of my research on onion and garlic intolerances, and then additional research looking into GI things, I realized that the low FODMAP diet which is typically prescribed for IBS/IBD (which I don’t have) could be something I could try without a lot of risk: if it helped, that would be an improvement, regardless of whatever I actually had.

So in August 2021, as noted in this blog post, I began the low FODMAP diet first starting with a careful elimination phase followed by testing and adding foods back into my diet. It helped, but over time I’ve realized that I still get symptoms (such as extreme quantities of gas, abdominal discomfort and distention, changed bathroom habits) even when I’m eating low FODMAP. It’s possible low FODMAP itself helped by avoiding certain types of food, but it’s also possible that it was helping because I was being so careful about the portions and timing of when I was eating, to avoid “stacking” FODMAPs.

One other thing I had tried, as I realized my onion and garlic intolerance was likely tied to being “fructans”, and that I had discovered I was sensitive to fructans in other foods, was an enzyme powder called Fodzyme. (I have no affiliation with this company, FYI). The powder works to target the FODMAPs in food to help neutralize them so they don’t cause symptoms. It worked for me on the foods I had experimented with, and it allowed me to eat food that had onion powder or garlic powder listed as a minor ingredient (I started small and cautious and am working my way up in testing other foods and different quantities). I longingly wished that there were other enzymes I could take to help improve digestion, because Fodzyme seemed to not only reduce the symptoms I had after I ate, but also seemed to improve my digestion overall (e.g. improved stool formation). I did some research but “digestive enzymes” are generally looked down upon and there’s no good medical research, so I chalked it up to snake oil and didn’t do anything about it.

Until, oddly enough, in November 2021 I noticed a friend’s social media post talking about their dog being diagnosed with exocrine pancreatic insufficiency (EPI). It made me go look up EPI in humans to see if it was a thing, because their experience sounded a lot like mine. Turns out, EPI is a thing, and it’s very common in humans who have cystic fibrosis; pancreas-related surgeries or pancreatic cancer; and there is also a known correlation with people with type 1 diabetes or with celiac disease.

Oh hey, that’s me (celiac and type 1 diabetes).

I did more research and found that various studies estimate 40% of people with type 1 diabetes have low levels of pancreatic elastase, which is a proxy for determining if you have insufficient enzymes being produced by your pancreas to help you digest your food. The causal mechanism is unclear, so they don’t know whether it’s just a ‘complication’ and side effect of diabetes and the pancreas no longer producing insulin, or if there is something else going on.

Given the ties to diabetes and celiac, I reached out to my GI doctor again in December 2021 and asked if I should get my pancreatic elastase levels tested to check for exocrine pancreatic insufficiency (EPI), given that my symptoms matching the textbook definition and my risk factors of diabetes and celiac. He said sure, sent in the lab request, and I got the lab work done. My results are on the borderline of ‘moderate’ insufficiency, and given my very obvious and long-standing symptoms, and given my GI doc said there would be no harm from trying, I start taking pancreatic enzyme replacement therapy (called PERT). Basically, this means I swallow a pill that contains enzymes with the first bite of food that I eat, and the enzymes help me better digest the food I am eating.

And guess what? For me, it works and definitely has helped reduce symptoms after I’m eating and with next-day bathroom habits. So I consider myself to have mild or moderate exocrine pancreatic insufficiency (EPI).

(Also, while I was waiting on my test results to come back, I found that there is a lipase-only version of digestive enzymes available to purchase online, so I got some lipase and began taking it. It involves some titration to figure out how much I needed, but I saw some improvement already from low doses of lipase, so that also led me to want to try PERT, which contains all 3 types of enzymes your pancreas normally naturally produces, even though my elastase levels were on the borderline of ‘moderate’ insufficiency. Not everyone with lower levels of elastase has insufficiency in enzymes, but my symptoms and response to lipase and PERT point to the fact that I personally do have some insufficiency.)

More about my experiences with exocrine pancreatic insufficiency

Unfortunately, there is no cure for exocrine pancreatic insufficiency. Like Type 1 diabetes, it requires lifelong treatment. So, I will be taking insulin and now PERT likely for the rest of my life. Lazy pancreas! (Also, it’s possible I will need to increase my PERT dose over time if my insufficiency increases.)

Why treat EPI? Well, beyond managing very annoying symptoms that impact quality of life, if left untreated it’s associated with increased mortality (e.g. dying earlier than you would otherwise) due to malnutrition (because you’re not properly absorbing the nutrients in the food you’re eating) and bone density problems.

Oddly enough, there seem to be two versions of the name (and therefore two acronyms) for the same thing: EPI and PEI, meaning exocrine pancreatic insufficiency or pancreatic exocrine insufficiency. I haven’t found a good explanation for why there are two names and if there are any differences. Luckily, my research into the medical literature shows they both pop up in search results pretty consistently, so it’s not like you end up missing a big body of literature if you use one search term or the other.

Interestingly, I learned 90% of people with cystic fibrosis may need PERT, and thankfully my friend with CF didn’t mind me reaching out to ask her if she had ever taken PERT or had any tips to give me from her knowledge of the CF community. That was nice that it turns out I do know some other people with EPI/PEI, even though they don’t usually talk about it because it seems to go hand in hand with CF. Some of the best resources of basic information about EPI/PEI are written either by CF foundations or by pancreatic cancer-related organizations, because those are the two biggest associated conditions that also link to EPI/PEI. There are also other conditions like diabetes and celiac with strong correlations, but these communities don’t seem to talk about it or have resources focused on it. (As with low FODMAP resources where everything is written for IBS/IBD, you can extrapolate and ignore everything that’s IBS/IBD specific. Don’t be afraid to read EPI/PEI information from communities that aren’t your primary community!)

Sadly, like so many GI conditions (remember in the intro I referenced 7 years average diagnosis time with celiac), it seems ridiculously hard to get to a diagnosis of EPI. I essentially self-diagnosed myself (and confirmed the diagnosis in partnership with my GI doc who agreed to run the tests). I am still very surprised that it never came up on his list of possible conditions despite having symptoms that are textbook EPI and having diabetes and celiac, which are known correlations. Apparently, this is common: I read one study that says even people with super high-risk factors (e.g. pancreas surgery, pancreatic cancer) aren’t necessarily screened, either! So it’s not just me falling through the cracks, and this is something the gastroenterology world needs to be better about. It’s also common for patients to bring this up to their doctors vs their doctors suggesting it as a potential diagnosis – this study found 24% of people brought up EPI, like I did, to their doctors.

Also, unfortunately, I had a few people (including family members) suggest to me in the last two years that my symptoms are psychosomatic, or stress-related. They’re clearly, as proven by lab work, not psychosomatic or stress-related but are a result of my exocrine pancreatic functions failing. Please, don’t ever suggest someone dealing with GI issues is experiencing symptoms due to stress – this is the kind of comment you should keep to yourself. (The last time someone mentioned this to me was months ago, and it still bothers me to think about it.)

Advocate for yourself

One of the very important things I learned early on when living with type 1 diabetes was the importance of knowing my own body, and advocating for myself. This unfortunately was a hard lesson learned, because I had general practice (GP or primary care / PCP) doctors who would refuse to treat me because I had diabetes because they were concerned about prescribing something that would mess up my blood sugars. They’d completely ignore the point that whatever infection I had would cause MORE disruption to my blood sugars by having me be sick and suffer longer, than I would have disruption to my blood sugar levels from a prescription. Sigh. So for the last almost two decades, I have had to go into every health encounter prepared to advocate for myself and make sure I get the medical expertise for whatever I’m there for, and not the less experienced take on diabetes (assuming I wasn’t there for diabetes, which I usually wasn’t).

This has translated into how I approached finding solutions for my GI symptoms. Per my history described above, I had increasing but minor GI symptoms from February-July 2020. Having new, stabbing pains in my abdomen led me to the gastroenterologist for a long list of testing for various things, but I had to continue to push for the next round of testing and schedule and manage everything to proceed through the list we had discussed at my appointment. Later, after we ran through the list, I had to try things like low FODMAP for myself, and then do additional research and identify the test for EPI as a likely next step to try.

I felt a little like the ‘boiling frog’ analogy, where my symptoms gradually worsened over time, but they weren’t startling bad (except for the points in time when I had stabbing abdominal pain). Or the two times, almost one year apart (Oct 2020 and Dec 2021) where I had what I considered bad “flares” of something where I got really hot and feeling really ill all of a sudden, but it wasn’t COVID-19 and it wasn’t anything specific causing it, there were no obvious food triggers, and the only thing I could do was lay down for 2-3 hours and rest before I started to feel better. Those were probably correlated with “overdoing it” with physical activity, but I’ve also run a marathon and a 50k ultramarathon in the last year and didn’t have problems on those days, so there’s not a certain threshold of activity that appears to cause that. Thankfully, that has only happened two times.

Other than those scenarios, it wasn’t like breaking my ankle where there was a clear “everything was fine and now something is broken”, but it was more like “I have had not-good-digestion and various increasing GI symptoms that don’t fit any clear problem or diagnosis on our shortlist of the 5 likely things it might be. It’s not excruciating but it is increasingly impacting my quality of life, and twisting myself into a pretzel with an evolving pattern of dietary modifications is not solving it”. It took me continuing to advocate for myself and not accepting suffering for the rest of my life (hopefully!) with these symptoms to get to an answer, which for me, so far, seems to be moderate exocrine pancreatic insufficiency.

What it’s like to start taking pancreatic enzyme replacement therapy (PERT)

PERT is typically measured by the units/amount of lipase it contains, even though it contains all 3 types of enzymes. (Some of the Medicare documents in different states actually are really helpful for comparing the size of dosing across the different brands of PERT. That also helped me look up the various brands in my insurance plan to see whether there would be a price difference between two of the most common brands.) Depending on symptoms and your level of insufficiency, like insulin, it requires some titration to figure out the right doses. I’ve been attempting to track generally the amount of fat that I’m eating to try to get a sense of my “ratio” of fat to lipase needed, although the research shows there is likely not a linear correlation between grams of fat and units of lipase needed. Another way to think about it is at what level of grams of fat in your meal do you need more than your current dose. For example, one pill of PERT at my current dose seems to work up to around 70 or so grams of fat per meal, as long as it doesn’t have more than 50% protein. Meals containing much more fat (120 g or so) definitely require more, as do meals with either a higher quantity of protein or a closer ratio of 1:1 fat to protein.

Different people have different needs with regard to whether they need enzyme support “just” for fat, or also for protein and carbs. I appear to at least need some support for carbs as well as protein, but am still establishing at what levels I need which dosing of which enzymes.

Personally, I am tracking to see whether my symptoms are reduced or eliminated in the hours following my meals (gas, abdominal discomfort, a sick feeling after eating) as well as the next day (bloating/abdominal distension, bathroom habits such as reduced steatorrhea), and overall whether I have any more of those really bad “flares”. My initial tests of taking PERT show improvements after my meals (I don’t feel sick after I eat anymore!) and often the next day.

After the first few days of trying food that was low FODMAP but giving me minor symptoms before PERT, I’ve also felt confident enough to try meals that I’ve avoided eating for over a year, such as a gluten free burger from one of our nearby local favorites! Even though it’s been well over a year since I’ve had it last, I immediately could tell a difference in how I felt eating it, due to taking PERT with it. There was no wave of fatigue before I was halfway through the burger, and no gas or feeling sick to my stomach after eating. I had clearly forgotten what it was like to not feel miserable after eating and to actually enjoy eating food! So far, PERT has been exceeding my expectations (although those were rather low).

It makes it slightly less annoying, then, to think about the price of PERT. Roughly, one month of PERT at the dosage I’m currently on costs the same as 3 vials of insulin in the US (in the ballpark of $800). Like insulin, PERT is necessary and worthwhile (and thankfully I do have health insurance).

Pancreases are great when they work…and expensive to replace!

A play on the spiderman meme of two spiderman's pointing at each other, indicating similar things. Labeled "exocrine pancreatic functions" and "endocrine pancreatic functions", indicating both of mine are not working as they should be.

TLDR: I have a new thing, exocrine pancreatic insufficiency, to deal with. Thankfully, there’s a treatment (PERT) that I can use to reduce symptoms and hopefully limit the potential impacts on morbidity long term. If you have diabetes or celiac and you have unexplained GI symptoms over time, you might want to do some research into EPI and discuss it with your gastroenterologist.

Also…for any endocrinologist reading this…or any other healthcare providers…if you have patients with diabetes and suspected GI issues, please consider EPI as a possible diagnosis once you’ve ruled out celiac disease and other likely suspects. Given the high rates of lowered elastase in all types of diabetes, it’s worth screening for EPI in patients with otherwise-unexplained steatorrhea or similar symptoms.

PS – if you land on this post and haven’t seen it already, you may want to check out PERT Pilot, the first iOS app for Exocrine Pancreatic Insufficiency! It’s an iOS app that I built that allows you to record as many meals as you want, the PERT dosing and outcomes, to help you visualize and review more of your PERT dosing data!


You can also contribute to a research study and help us learn more about EPI/PEI – take this anonymous survey to share your experiences with EPI-related symptoms!

Looking back at work and accomplishments in 2021

I decided to do a look back at the last year’s worth of work, in part because it was a(nother) weird year in the world and also because, if you’re interested in my work, unless you read every single Tweet, there may have been a few things you missed that are of interest!

In general, I set goals every year that stretch across personal and professional efforts. This includes a daily physical activity streak that coincides with my walking and running lots of miles this year in pursuit of my second marathon and first (50k) ultramarathon. It’s good for my mental and physical health, which is why I post almost daily updates to help keep myself accountable. I also set goals like “do something creative” which could be personal (last year, knitting a new niece a purple baby blanket ticked the box on this goal!) or professional. This year, it was primarily professional creativity that accomplished this goal (more on that below).

Here’s some specifics about goals I accomplished:

RUNNING

  • My initial goal was training ‘consistently and better’ than I did for my first marathon, with 400 miles as my stretch goal if I was successfully training for the marathon. (Otherwise, 200 miles for the year would be the goal without a marathon.) My biggest-ever running year in 2013 with my first marathon was 356 miles, so that was a good big goal for me. I achieved it in June!
  • I completed my second marathon in July, and PR’d by over half an hour.
  • I completed my first-ever ultramarathon, a 50k!
  • I re-set my mileage goal after achieving 400 miles..to 500..600…etc. I ultimately achieved the biggest-ever mileage goal I’ve ever hit and think I ever will hit: I ran 1,000 miles in a single year!
  • I wrote lots of details about my methods of running (primarily, run/walking) and running with diabetes here. If you’re looking for someone to cheer you on as you set a goal for daily activity, like walking, or learning to run, or returning to running…DM or @ me on Twitter (@DanaMLewis). I love to cheer people on as they work toward their activity goals! It helps keep me inspired, too, to keep aiming at my own goals.

CREATIVITY

  • My efforts to be creative were primarily on the professional side this year. The “Convening The Center” project ended up having 2 out of 3 of my things that I categorized as being creative. The first was the design of the digital activities and the experience of CTC overall (more about that here). The second were the items in the physical “kit” we mailed out to participants: we brainstormed and created custom playing cards and physical custom keychains. They were really fun to make, especially in partnership with our excellent project artist, Rebeka Ryvola, who did the actual design work!
  • My third “creative” endeavor was a presentation, but it was unlike the presentations I usually give. I was tasked to create a presentation that was “visually engaging” and would not involve showing my face in the presentation. I’ve linked to the video below in the presentation section, but it was a lot of work to think about how to create a visually and auditory focused presentation and try to make it engaging, and I’m proud of how it turned out!

RESEARCH AND PUBLICATIONS

  • This is where the bulk of my professional work sits right now. I continue to be a PI on the CREATE trial, the world’s first randomized control trial assessing open-source automated insulin delivery technology, including the algorithm Scott and I dreamed up and that I have been using every day for the past 7 years. The first data from the trial itself is forthcoming in 2022. 
  • Convening The Center also was a grant-funded project that we turned into research with a publication that we submitted, assessing more of what patients “do”, which is typically not assessed by researchers and those looking at patient engagement in research or innovation. Hopefully, the publication of the research article we just submitted will become a 2022 milestone! In the meantime, you can read our report from the project here (https://bit.ly/305iQ1W ), as this grant-funded project is now completed.
  • Goal-wise, I aim to generate a few publications every year. I do not work for any organization and I am not an academic. However, I come from a communications background and see the benefit of reaching different audiences where they are, which is why I write blog posts for the patient community and also seek to disseminate knowledge to the research and clinical communities through traditional peer-reviewed literature. You can see past years’ research articulated on my research page (DIYPS.org/research), but here’s a highlight of some of the 2021 publications:
  • Also, although I’m not a traditional academic researcher, I also participate in the peer review process and frequently get asked to peer-review submitted articles to a variety of journals. I skimmed my email and it looks like I completed (at least) 13 peer reviews, most of which included also reviewing subsequent revisions of those submitted articles. So it looks like my rate of peer reviewing (currently) is matching my rate of publishing. I typically get asked to review articles related to open-source or DIY diabetes technology (OpenAPS, AndroidAPS, Loop, Nightscout, and other efforts), citizen science in healthcare, patient-led research or patient engagement in research, digital health, and diabetes data science. If you’re submitting articles on that topic, you’re welcome to recommend me as a potential reviewer.

PRESENTATIONS

  • I continued to give a lot of virtual presentations this year, such as at conferences like the “Insulin100” celebration conference (you can see the copy I recorded of my conference presentation here). I keynoted at the European Patients Forum Congress as well as at ADA’s Precision Diabetes Medicine 2021; an invited talk ADA Scientific Sessions (session coverage here); the 2021 Federal Wearables Summit: (video here); and the BIH Clinician Scientist Symposium (video here), to name a few (but not all).
  • Additionally, as I mentioned, one of the presentations I’m most proud of was created for the Fall 2021 #DData Exchange event:

OTHER STUFF

I did quite a few other small projects that don’t fit neatly into the above categories.

One final thing I’m excited to share is that also in 2021, Amazon came out with a beta program for producing hardcover/hardback books, alongside the ability to print paperback books on demand (and of course Kindle). So, you can now buy a copy of my book about Automated Insulin Delivery: How artificial pancreas “closed loop” systems can aid you in living with diabetes in paperback, hardback, or on Kindle. (You can also, still, read it 100% for free online via your phone or desktop at ArtificialPancreasBook.com, or download a PDF for free to read on your device of choice. Thousands of people have downloaded the PDF!)

Now available in hardcover, the book about Automated Insulin Delivery by Dana M. Lewis

How to deal with wildfire smoke and air quality issues during COVID-19

2020. What a year. We’ve been social distancing since late February and being very careful in terms of minimizing interactions even with family, for months. We haven’t traveled, we haven’t gone out to eat, and we basically only go out to get exercise (with a mask when it’s on hiking trails/around anyone) or Scott goes to the grocery store (n95 masked). We’ve been working on CoEpi (see CoEpi.org – an open source exposure notification app based on symptom reports) and staying on top of the scientific literature around COVID-19, regarding NPIs like distancing and masking; at-home diagnostics like temperature and pulse oximetry monitoring, prophylactics and treatments like zinc, quercetine, and even MMR vaccines; and the impact of ventilation and air quality on COVID-19 transmission and susceptibility.

And we live in Washington, so the focus on air quality got very real very quickly during this year’s wildfire season, where we had wildfires across the state of Washington, then got pummeled for over a week with hazardous levels of wildfire smoke coming up from Oregon and California to cover our existing smoke layer. But, one of our DIY air quality hacks for COVID-19 gave us a head start on air quality improvements for smoke-laden air, which I’ll describe below.

Here are various things we’ve gotten and have been using in our personal attempts to thwart COVID-19:

  • Finger pulse oximeter.
    • Just about any cheap pulse oximeter you can find is fine. The goal is to get an idea of your normal baseline oxygen rates. If you dip low, that might be a reason to go to urgent care or the ER or at least talk to your doctor about it. For me, I am typically 98-99% (mine doesn’t read higher than 99%), and my personal plan would be to talk to a healthcare provider if I was sick and started dropping below 94%.
  • Thermometer
    • Use any thermometer that you’ll actually use. I have previously used a no-touch thermometer that could read foreheads but found it varied widely and inconsistently, so I went back to an under the tongue thermometer and took my temperature for several months at different times to figure out my baselines. If sick or you have a suspected exposure, it’s good to be checking at different times of the day (people often have lower temps in the morning than in the evening, so knowing your daily differences may help you evaluate if you’re elevated for you or not).
    • Note: women with menstrual cycles may have changes related to this; such as lower baseline temps at the start of the cycle and having a temperature upswing around or after the mid-point in their cycle. But not all do. Also, certain medications or birth controls can impact basal temperatures, so be aware of that.
  • Originally, n95 masks with outlet valves.
    • Note: n95 masks with valves cannot be used by medical professionals, because the valves make them less effective for protecting others. (So don’t freak out at people who had a box of valved n95 masks from previous wildfire smoke seasons, as we did. Ahem.) 
    • We had a box we bought after previous years’ wildfire smoke, and they work well for us (in low-risk non-medical settings) for repeated use. They’re Scott’s go-to choice. If you’re in a setting where the outlet valve matters (indoors in a doctor’s/medical setting, or on a plane), you can easily pop a surgical/procedure mask over the valve to block the valve to protect others from your exhaust, while still getting good n95-level protection for yourself.
    • They were out of stock since February, but given the focus on n95 without valves for medical PPE, there have been a few boxes of n95 masks with outlet valves showing up online at silly prices ($7 per mask or so). But, kn95’s are a cheaper per mask option that are generally more available – see below.
    • (June 2021 note – they are back to reasonable prices, in the $1-2 range per mask on Amazon, and available again.)
  • kn95 masks.
    • kn95 masks are a different standard than US-rated n95; but they both block 95% of tiny (0.3 micron) particles. For non-medical usage, we consider them equivalent. But like n95, the fit is key.
    • We originally bought these kn95s, but the ear loops were quite big on me. (See below for options if this is the case on any you get.) They aren’t as hardy as the n95s with valves (above); the straps have broken off, tearing the mask, after about 4-5 long wears. That’s still worth it for them being $2-3 each (depending on how many you buy at a time) for me, but I’d always pack a spare mask (of any kind) just in case.
      • Option one to adjust ear loops: I loop them over my ponytail, making them head loops. This has been my favorite kn95 option because I get a great fit and a tight seal with this method.
      • Option two to adjust ear loops: tie knots in the ear loops
      • Option three to adjust ear loops: use things like this to tighten the ear loops
    • We also got a set of these kn95s. They don’t fit quite as well in terms of a tight face fit, but these actually work as ear loops (as designed), and I was able to wear this inside the house on the worst day of air quality.
  • Box fan with a filter to reduce COVID-19 particles in the air:
    • We read this story about using an existing AC air furnace filter on a box fan to help reduce the number of COVID-19 particles in the air. We already had a box fan, so we took one of our spare 20×20 filters and popped it on. I’m allergic to dust, cats (which we just got), trees, grass, etc, so I knew it would also help with regular allergens. There are different levels of filter – all the way up to HEPA filters – but we had MERV 12 so that’s what we used.
  • Phone/object UV sanitizer
    • We got a PhoneSoap Pro (in lavender, but there are other colors). Phones are germy, and being able to pop the phone in (plus keys or any other objects like credit cards or insurance cards that might have been handled by another human) to disinfect has been nice to have.
    • The Pro is done sanitizing in 5 minutes, vs the regular one takes 10 minutes. It’s not quite 2x the price as the non-pro, but I’ve found it to be worthwhile because otherwise, I would be impatient to get my phone back out. I usually pop my phone in it when I get home from my walk, and by the time I’m done washing my hands and all the steps of getting home, the phone is about or already done being sanitized.
  • Bonus (but not as useful to everyone as the above, and pricey): Oura ring
    • Scott and I also both got Oura rings. They are pricey, but every morning when we wake up we can see our lowest resting heart rate (RHR), heart rate variability (HRV), temperature deviations, and respiratory rate (RR). There have been studies showing that HRV, RHR, overnight temperature, and RR changes happen early in COVID-19 and other infections, which can give an early warning sign that you might be getting sick with something. That can be a good early warning sign (before you get to the point of being symptomatic and highly infectious) that you need to mask up and work from home/social distance/not interact with other people if you can help it. I find the data soothing, as I am used to using a lot of diabetes data on a daily and real-time basis (see also: invented an open source artificial pancreas). Due to price and level of interest in self-tracking data, this may not be a great tool for everyone.
    • Note this doesn’t tell you your temperature in real time, or present absolute values, but it’s helpful to see, and get warnings about, any concerning trends in your body temperature data. I’ve seen several anecdotal reports of this being used for early detection of COVID-19 infection and various types of relapses experienced by long-haulers.

And here are some things we’ve added to battle air quality during wildfire smoke season:

  • We were already running a box fan with a filter (see above for more details) for COVID-19 and allergen reduction; so we kept running it on high speed for smoke reduction.
    • Basic steps: get box fan, get a filter, and duct tape or strap it on. Doesn’t have to be cute, but it will help.
    • I run this on high speed during the day in my bedroom, and then on low speed overnight or sleep with earplugs in.
  • We already had a small air purifier for allergens, which we also kept running on high. This one hangs out in our guest bedroom/my office.
  • We caved and got a new, bigger air purifier, since we expect future years to be equally and unfortunately as smoky. This is the new air purifier we got. (Scott chose the 280i version that claims to cover 279 sq. ft.). It’s expensive, but given how miserable I was even inside the house with decent air quality thanks to my box fan and filter, little purifier, and our A/C filtered air… I consider it to be worth the investment.
    • We plugged it in and validated that with our A/C-filtered air combined with my little air purifier and the box fan with filter running on high, we already had ‘good’ air quality (but not excellent). We also stuck it out in the hallway to see what the hallway air quality was running – around 125 ug/m^3 – yikes. Turns out that was almost as high as the outside air, which is I’ve had to wear a kn95 mask even to walk hallway laps, and why my eyes are irritated. example air quality difference between hallway and our kitchen. hallway is much higher.
  • Check your other filters while you’re on air quality monitoring alert. We found our A/C intake duct vent had not had the air filter changed since we moved in over a year ago… and turns out it’s a non-standard size and had a hand-cut stuffed in there, so we ordered a correctly sized one for the vent, and taped a different one over the outside in the interim.
  • The other thing to fight the smoke is having n95 with valves or kn95 masks to wear when we have to go outside, or if it gets particularly bad inside. Our previous strategy was to have several on hand for wildfire season, and we’ll continue to do this. (See above in the COVID-19 section for descriptions in more detail about different kinds of masks we’ve tried.)
  • 2022 update: I got a mini personal air purifier to try for travel (to help reduce risk of COVID-19 in addition to all other precautions like staying masked on planes and indoor spaces), but it also turned out to be beneficial inside during the worst of our 2022 wildfire smoke season. I had a slightly scratchy throat even with two box fans and two different air purifiers inside; but keeping this individual one plugged in and pointed at my face overnight eliminated me waking up with a scratchy throat. That’s great for wildfire smoke, and also shows that there is some efficacy to this fan for it’s intended purpose, which is improving air around my face during travel in inside spaces for COVID-19 and other disease prevention.

Wildfires, their smoke, and COVID-19 combined is a bit of a mess for our health. Stay inside when you can, wear masks when you’re around other people outside your household that you have to share air with, wash your hands, and good luck.

Poster and presentation content from @DanaMLewis at #ADA2020 and #DData20

In previous years (see 2019 and 2018), I mentioned sharing content from ADA Scientific Sessions (this year it’s #ADA2020) with those not physically present at the conference. This year, NO ONE is present at the event, and we’re all virtual! Even more reason to share content from the conference. :)

I contributed to and co-authored two different posters at Scientific Sessions this year:

  • “Multi-Timescale Interactions of Glucose and Insulin in Type 1 Diabetes Reveal Benefits of Hybrid Closed Loop Systems“ (poster 99-LB) along with Azure Grant and Lance Kriegsfeld, PhD.
  • “Do-It-Yourself Artificial Pancreas Systems for Type 1 Diabetes Reduce Hyperglycemia Without Increasing Hypoglycemia” (poster 988-P in category 12-D Clinical Therapeutics/New Technology—Insulin Delivery Systems), alongside Jennifer Zabinsky, MD MEng, Haley Howell, MSHI, Alireza Ghezavati, MD, Andrew Nguyen, PhD, and Jenise Wong, MD PhD.

And, while not a poster at ADA, I also presented the “AID-IRL” study funded by DiabetesMine at #DData20, held in conjunction with Scientific Sessions. A summary of the study is also included in this post.

First up, the biological rhythms poster, “Multi-Timescale Interactions of Glucose and Insulin in Type 1 Diabetes Reveal Benefits of Hybrid Closed Loop Systems” (poster 99-LB). (Twitter thread summary of this poster here.)

Building off our work as detailed last year, Azure, Lance, and I have been exploring the biological rhythms in individuals living with type 1 diabetes. Why? It’s not been done before, and we now have the capabilities thanks to technology (pumps, CGM, and closed loops) to better understand how glucose and insulin dynamics may be similar or different than those without diabetes.

Background:

Mejean et al., 1988Blood glucose and insulin exhibit coupled biological rhythms at multiple timescales, including hours (ultradian, UR) and the day (circadian, CR) in individuals without diabetes. The presence and stability of these rhythms are associated with healthy glucose control in individuals without diabetes. (See right, adapted from Mejean et al., 1988).

However, biological rhythms in longitudinal (e.g., months to years) data sets of glucose and insulin outputs have not been mapped in a wide population of people with Type 1 Diabetes (PWT1D). It is not known how glucose and insulin rhythms compare between T1D and non-T1D individuals. It is also unknown if rhythms in T1D are affected by type of therapy, such as Sensor Augmented Pump (SAP) vs. Hybrid Closed Loop (HCL). As HCL systems permit feedback from a CGM to automatically adjust insulin delivery, we hypothesized that rhythmicity and glycemia would exhibit improvements in HCL users compared to SAP users. We describe longitudinal temporal structure in glucose and insulin delivery rate of individuals with T1D using SAP or HCL systems in comparison to glucose levels from a subset of individuals without diabetes.

Data collection and analysis:

We assessed stability and amplitude of normalized continuous glucose and insulin rate oscillations using the continuous wavelet transformation and wavelet coherence. Data came from 16 non-T1D individuals (CGM only, >2 weeks per individual) from the Quantified Self CGM dataset and 200 (n = 100 HCL, n = 100 SAP; >3 months per individual) individuals from the Tidepool Big Data Donation Project. Morlet wavelets were used for all analyses. Data were analyzed and plotted using Matlab 2020a and Python 3 in conjunction with in-house code for wavelet decomposition modified from the “Jlab” toolbox, from code developed by Dr. Tanya Leise (Leise 2013), and from the Wavelet Coherence toolkit by Dr. Xu Cui. Linear regression was used to generate correlations, and paired t-tests were used to compare AUC for wavelet and wavelet coherences by group (df=100). Stats used 1 point per individual per day.

Wavelets Assess Glucose and Insulin Rhythms and Interactions

Wavelet Coherence flow for glucose and insulin

Morlet wavelets (A) estimate rhythmic strength in glucose or insulin data at each minute in time (a combination of signal amplitude and oscillation stability) by assessing the fit of a wavelet stretched in window and in the x and y dimensions to a signal (B). The output (C) is a matrix of wavelet power, periodicity, and time (days). Transform of example HCL data illustrate the presence of predominantly circadian power in glucose, and predominantly 1-6 h ultradian power in insulin. Color map indicates wavelet power (synonymous with Y axis height). Wavelet coherence (D) enables assessment of rhythmic interactions between glucose and insulin; here, glucose and insulin rhythms are highly correlated at the 3-6 (ultradian) and 24 (circadian) hour timescales.

Results:

Hybrid Closed Loop Systems Reduce Hyperglycemia

Glucose distribution of SAP, HCL, and nonT1D
  • A) Proportional counts* of glucose distributions of all individuals with T1D using SAP (n=100) and HCL (n=100) systems. SAP system users exhibit a broader, right shifted distribution in comparison to individuals using HCL systems, indicating greater hyperglycemia (>7.8 mmol/L). Hypoglycemic events (<4mmol/L) comprised <5% of all data points for either T1D dataset.
  • B) Proportional counts* of non-T1D glucose distributions. Although limited in number, our dataset from people without diabetes exhibits a tighter blood glucose distribution, with the vast majority of values falling in euglycemic range (n=16 non-T1D individuals).
  • C) Median distributions for each dataset.
  • *Counts are scaled such that each individual contributes the same proportion of total data per bin.

HCL Improves Correlation of Glucose-Insulin Level & Rhythm

Glucose and Insulin rhythms in SAP and HCL

SAP users exhibit uncorrelated glucose and insulin levels (A) (r2 =3.3*10-5; p=0.341) and uncorrelated URs of glucose and insulin (B) (r2 =1.17*10-3; p=0.165). Glucose and its rhythms take a wide spectrum of values for each of the standard doses of insulin rates provided by the pump, leading to the striped appearance (B). By contrast, Hybrid Closed Loop users exhibit correlated glucose and insulin levels (C) (r2 =0.02; p=7.63*10-16), and correlated ultradian rhythms of glucose and insulin (D) (r2 =-0.13; p=5.22*10-38). Overlays (E,F).

HCL Results in Greater Coherence than SAP

Non-T1D individuals have highly coherent glucose and insulin at the circadian and ultradian timescales (see Mejean et al., 1988, Kern et al., 1996, Simon and Brandenberger 2002, Brandenberger et al., 1987), but these relationships had not previously been assessed long-term in T1D.

coherence between glucose and insulin in HCL and SAP, and glucose swings between SAP, HCL, and non-T1DA) Circadian (blue) and 3-6 hour ultradian (maroon) coherence of glucose and insulin in HCL (solid) and SAP (dotted) users. Transparent shading indicates standard deviation. Although both HCL and SAP individuals have lower coherence than would be expected in a non-T1D individual,  HCL CR and UR coherence are significantly greater than SAP CR and UR coherence (paired t-test p= 1.51*10-7 t=-5.77 and p= 5.01*10-14 t=-9.19, respectively). This brings HCL users’ glucose and insulin closer to the canonical non-T1D phenotype than SAP users’.

B) Additionally, the amplitude of HCL users’ glucose CRs and URs (solid) is closer (smaller) to that of non-T1D (dashed) individuals than are SAP glucose rhythms (dotted). SAP CR and UR amplitude is significantly higher than that of HCL or non-T1D (T-test,1,98, p= 47*10-17 and p= 5.95*10-20, respectively), but HCL CR amplitude is not significantly different from non-T1D CR amplitude (p=0.61).

Together, HCL users are more similar than SAP users to the canonical Non-T1D phenotype in A) rhythmic interaction between glucose and insulin and B) glucose rhythmic amplitude.

Conclusions and Future Directions

T1D and non-T1D individuals exhibit different relative stabilities of within-a-day rhythms and daily rhythms in blood glucose, and T1D glucose and insulin delivery rhythmic patterns differ by insulin delivery system.

Hybrid Closed Looping is Associated With:

  • Lower incidence of hyperglycemia
  • Greater correlation between glucose level and insulin delivery rate
  • Greater correlation between ultradian glucose and ultradian insulin delivery rhythms
  • Greater degree of circadian and ultradian coherence between glucose and insulin delivery rate than in SAP system use
  • Lower amplitude swings at the circadian and ultradian timescale

These preliminary results suggest that HCL recapitulates non-diabetes glucose-insulin dynamics to a greater degree than SAP. However, pump model, bolusing data, looping algorithms and insulin type likely all affect rhythmic structure and will need to be further differentiated. Future work will determine if stability of rhythmic structure is associated with greater time in range, which will help determine if bolstering of within-a-day and daily rhythmic structure is truly beneficial to PWT1D.
Acknowledgements:

Thanks to all of the individuals who donated their data as part of the Tidepool Big Data Donation Project, as well as the OpenAPS Data Commons, from which data is also being used in other areas of this study. This study is supported by JDRF (1-SRA-2019-821-S-B).

(You can download a full PDF copy of the poster here.)

Next is “Do-It-Yourself Artificial Pancreas Systems for Type 1 Diabetes Reduce Hyperglycemia Without Increasing Hypoglycemia” (poster 988-P in category 12-D Clinical Therapeutics/New Technology—Insulin Delivery Systems), which I co-authored alongside Jennifer Zabinsky, MD MEng, Haley Howell, MSHI, Alireza Ghezavati, MD, Andrew Nguyen, PhD, and Jenise Wong, MD PhD. There is a Twitter thread summarizing this poster here.

This was a retrospective double cohort study that evaluated data from the OpenAPS Data Commons (data ranged from 2017-2019) and compared it to conventional sensor-augmented pump (SAP) therapy from the Tidepool Big Data Donation Project.

Methods:

  • From the OpenAPS Data Commons, one month of CGM data (with more than 70% of the month spent using CGM), as long as they were >1 year of living with T1D, was used. People could be using any type of DIYAPS (OpenAPS, Loop, or AndroidAPS) and there were no age restrictions.
  • A random age-matched sample from the Tidepool Big Data Donation Project of people with type 1 diabetes with SAP was selected.
  • The primary outcome assessed was percent of CGM data <70 mg/dL.
  • The secondary outcomes assessed were # of hypoglycemic events per month (15 minutes or more <70 mg/dL); percent of time in range (70-180mg/dL); percent of time above range (>180mg/dL), mean CGM values, and coefficient of variation.
Methods_DIYAPSvsSAP_ADA2020_DanaMLewis

Demographics:

  • From Table 1, this shows the age of participants was not statistically different between the DIYAPS and SAP cohorts. Similarly, the age at T1D diagnosis or time since T1D diagnosis did not differ.
  • Table 2 shows the additional characteristics of the DIYAPS cohort, which included data shared by a parent/caregiver for their child with T1D. DIYAPS use was an average of 7 months, at the time of the month of CGM used for the study. The self-reported HbA1c in DIYAPS was 6.4%.
Demographics_DIYAPSvsSAP_ADA2020_DanaMLewis DIYAPS_Characteristics_DIYAPSvsSAP_ADA2020_DanaMLewis

Results:

  • Figure 1 shows the comparison in outcomes based on CGM data between the two groups. Asterisks (*) indicate statistical significance.
  • There was no statistically significant difference in % of CGM values below 70mg/dL between the groups in this data set sampled.
  • DIYAPS users had higher percent in target range and lower percent in hyperglycemic range, compared to the SAP users.
  • Table 3 shows the secondary outcomes.
  • There was no statistically significant difference in the average number of hypoglycemic events per month between the 2 groups.
  • The mean CGM glucose value was lower for the DIYAPS group, but the coefficient of variation did not differ between groups.
CGM_Comparison_DIYAPSvsSAP_ADA2020_DanaMLewis SecondaryOutcomes_DIYAPSvsSAP_ADA2020_DanaMLewis

Conclusions:

    • Users of DIYAPS (from this month of sampled data) had a comparable amount of hypoglycemia to those using SAP.
    • Mean CGM glucose and frequency of hyperglycemia were lower in the DIYAPS group.
    • Percent of CGM values in target range (70-180mg/dL) was significantly greater for DIYAPS users.
    • This shows a benefit in DIYAPS in reducing hyperglycemia without compromising a low occurrence of hypoglycemia. 
Conclusions_DIYAPSvsSAP_ADA2020_DanaMLewis

(You can download a PDF of the e-poster here.)

Finally, my presentation at this year’s D-Data conference (#DData20). The study I presented, called AID-IRL, was funded by Diabetes Mine. You can see a Twitter thread summarizing my AID-IRL presentation here.

AID-IRL-Aim-Methods_DanaMLewis

I did semi-structured phone interviews with 7 users of commercial AID systems in the last few months. The study was funded by DiabetesMine – both for my time in conducting the study, as well as funding for study participants. Study participants received $50 for their participation. I sought a mix of longer-time and newer AID users, using a mix of systems. Control-IQ (4) and 670G (2) users were interviewed; as well as (1) a CamAPS FX user since it was approved in the UK during the time of the study.

Based on the interviews, I coded their feedback for each of the different themes of the study depending on whether they saw improvements (or did not have issues); had no changes but were satisfied, or neutral experiences; or saw negative impact/experience. For each participant, I reviewed their experience and what they were happy with or frustrated by.

Here are some of the details for each participant.

AID-IRL-Participant1-DanaMLewisAID-IRL-Participant1-cont_DanaMLewis1 – A parent of a child using Control-IQ (off-label), with 30% increase in TIR with no increased hypoglycemia. They spend less time correcting than before; less time thinking about diabetes; and “get solid uninterrupted sleep for the first time since diagnosis”. They wish they had remote bolusing, more system information available in remote monitoring on phones. They miss using the system during the 2 hour CGM warmup, and found the system dealt well with growth spurt hormones but not as well with underestimated meals.

AID-IRL-Participant2-DanaMLewis AID-IRL-Participant2-cont-DanaMLewis2 – An adult male with T1D who previously used DIYAPS saw 5-10% decrease in TIR (but it’s on par with other participants’ TIR) with Control-IQ, and is very pleased by the all-in-one convenience of his commercial system.He misses autosensitivity (a short-term learning feature of how insulin needs may very from base settings) from DIYAPS and has stopped eating breakfast, since he found it couldn’t manage that well. He is doing more manual corrections than he was before.

AID-IRL-Participant5-DanaMLewis AID-IRL-Participant5-cont_DanaMLewis5 – An adult female with LADA started, stopped, and started using Control-IQ, getting the same TIR that she had before on Basal-IQ. It took artificially inflating settings to achieve these similar results. She likes peace of mind to sleep while the system prevents hypoglycemia. She is frustrated by ‘too high’ target; not having low prevention if she disables Control-IQ; and how much she had to inflate settings to achieve her outcomes. It’s hard to know how much insulin the system gives each hour (she still produces some of own insulin).

AID-IRL-Participant7-DanaMLewis AID-IRL-Participant7-cont-DanaMLewis7 – An adult female with T1D who frequently has to take steroids for other reasons, causing increased BGs. With Control-IQ, she sees 70% increase in TIR overall and increased TIR overnight, and found it does a ‘decent job keeping up’ with steroid-induced highs. She also wants to run ‘tighter’ and have an adjustable target, and does not ever run in sleep mode so that she can always get the bolus corrections that are more likely to bring her closer to target.

AID-IRL-Participant3-DanaMLewis AID-IRL-Participant3-cont-DanaMLewis3 – An adult male with T1D using 670G for 3 years didn’t observe any changes to A1c or TIR, but is pleased with his outcomes, especially with the ability to handle his activity levels by using the higher activity target.  He is frustrated by the CGM and is woken up 1-2x a week to calibrate overnight. He wishes he could still have low glucose suspend even if he’s kicked out of automode due to calibration issues. He also commented on post-meal highs and more manual interventions.

AID-IRL-Participant6-DanaMLewis AID-IRL-Participant6-contDanaMLewis6 – Another adult male user with 670G was originally diagnosed with T2 (now considered T1) with a very high total daily insulin use that was able to decrease significantly when switching to AID. He’s happy with increased TIR and less hypo, plus decreased TDD. Due to #COVID19, he did virtually training but would have preferred in-person. He has 4-5 alerts/day and is woken up every other night due to BG alarms or calibration. He does not like the time it takes to charge CGM transmitter, in addition to sensor warmup.

AID-IRL-Participant4-DanaMLewis AID-IRL-Participant4-contDanaMLewis4 – The last participant is an adult male with T1 who previously used DIYAPS but was able to test-drive the CamAPS FX. He saw no TIR change to DIYAPS (which pleased him) and thought the learning curve was easy – but he had to learn the system and let it learn him. He experienced ‘too much’ hypoglycemia (~7% <70mg/dL, 2x his previous), and found it challenging to not have visibility of IOB. He also found the in-app CGM alarms annoying. He noted the system may work better for people with regular routines.

You can see a summary of the participants’ experiences via this chart. Overall, most cited increased or same TIR. Some individuals saw reduced hypos, but a few saw increases. Post-meal highs were commonly mentioned.

AID-IRL-UniversalThemes2-DanaMLewis AID-IRL-UniversalThemes-DanaMLewis

Those newer to CGM have a noticeable learning curve and were more likely to comment on number of alarms and system alerts they saw. The 670G users were more likely to describe connection/troubleshooting issues and CGM calibration issues, both of which impacted sleep.

This view highlights those who more recently adopted AID systems. One noted their learning experience was ‘eased’ by “lurking” in the DIY community, and previously participating in an AID study. One felt the learning curve was high. Another struggled with CGM.

AID-IRL-NewAIDUsers-DanaMLewis

Both previous DIYAPS users who were using commercial AID systems referenced the convenience factor of commercial systems. One DIYAPS saw decreased TIR, and has also altered his behaviors accordingly, while the other saw no change to TIR but had increased hypo’s.

AID-IRL-PreviousDIYUsers-DanaMLewis

Companies building AID systems for PWDs should consider that the onboarding and learning curve may vary for individuals, especially those newer to CGM. Many want better displays of IOB and the ability to adjust targets. Remote bolusing and remote monitoring is highly desired by all, regardless of age. Post-prandial was frequently mentioned as the weak point in glycemic control of commercial AID systems. Even with ‘ideal’ TIR, many commercial users still are doing frequent manual corrections outside of mealtimes. This is an area of improvement for commercial AID to further reduce the burden of managing diabetes.

AID-IRL-FeedbackForCompanies-DanaMLewis

Note – all studies have their limitations. This was a small deep-dive study that is not necessarily representative, due to the design and small sample size. Timing of system availability influenced the ability to have new/longer time users.

AID-IRL-Limitations-DanaMLewis

Thank you to all of the participants of the study for sharing their feedback about their experiences with AID-IRL!

(You can download a PDF of my slides from the AID-IRL study here.)

Have questions about any of my posters or presentations? You can always reach me via email at Dana@OpenAPS.org.

Automated Insulin Delivery: How artificial pancreas “closed loop” systems can aid you in living with diabetes (introducing “the APS book” by @DanaMLewis)

Tl;dr – I wrote a book about artificial pancreas systems / hybrid and fully closed loop systems / automated insulin delivery systems! It’s out today – you can buy a print copy on Amazon; a Kindle copy on Amazon; check out all the content on the web or your phone here; or download a PDF if you prefer.

A few months ago, I saw someone share a link to one of my old blog posts with someone else on Facebook. Quite old in fact – I had written it 5+ years ago! But the content was and is still relevant today.

It made me wonder – how could we as a diabetes community, who have been innovating and exploring new diabetes technology such as closed loop/artificial pancreas systems (APS), package up some of this knowledge and share it with people who are newer to APS? And while yes, much of this is tucked into the documentation for DIY closed loop systems, not everyone will choose a DIY closed loop system and also therefore may not see or find this information. And with regards to some of the things I’ve written here on DIYPS.org, not everyone will be lucky enough to have the right combination of search terms to end up on a particular post to answer their question.

Automated_Insulin_Delivery_by_DanaMLewis_example_covers_renderingThus, the idea for a book was born. I wanted to take much of what I’ve been writing here, sharing on Facebook and Twitter, and seeing others discuss as well, and put it together in one place to be a good starting place for someone to learn about APS in general. My hope is that it’s more accessible for people who don’t know what “DIY” or “open source” diabetes is, and it’s findable by people who also don’t know or don’t consider themselves to be part of the “diabetes online community”.

APSBook_NowAvailable_DanaMLewisIs it perfect? Absolutely not! But, like most of the things in the DIY community…the book is open source. Seriously. Here’s the repository on Github! If you see a typo or have suggestions of content to add, you can make a PR (pull request) or log an issue with content recommendations. (There’s instructions on the book page here with how to do either of those things!) I plan to make rolling updates to it, so you can see on the change log page what’s changed between major versions.)

It’s the first book out there that I know of on APS, but it won’t be the only one. I hope this inspires or moves more people to share their knowledge, through blogs or podcasts or future books, with the rest of our community and loved ones who want and need to learn more about managing type 1 diabetes.

“I will immediately recommend this book not just to people looking to use a DIY closed loop system, but also to anybody looking to improve their grasp on the management of type 1 diabetes, whether patient, caregiver, or healthcare provider.”

Aaron Neinstein, MD
Endocrinologist, UCSF

And as always, I’m happy to share what I’ve learned about the self-publishing process, too. I previously used CreateSpace for my children’s books, which got merged with Amazon’s Kindle Direct Publishing (KDP), and there was a learning curve for KDP for both doing the print version and doing the Kindle version. I didn’t get paid to write this book – and I didn’t write it for a profit. Like my children’s books, I plan to use any proceeds to donate copies to libraries and hospitals, and send any remaining funds to Life For A Child to help ensure as many kids as possible have access to insulin, BG monitoring supplies, and education.

I’m incredibly grateful for many people for helping out with and contributing to this book. You can see the full acknowledgement section with my immense thanks to the many reviewers of early versions of the book! And ditto for the people who shared their stories and experiences with APS. But special thanks go in particular to Scott for thorough first editing and overall support of every project I bring up out of the blue; to Tim Gunn for beautiful cover design of the book; and to Aaron Kowalski to be kind enough to write this amazing foreword.

Amazon_Button_APSBook_DanaMLewis

Presentations and poster content from @DanaMLewis at #ADA2019

Like I did last year, I want to share the work being presented at #ADA2019 with those who are not physically there! (And if you’re presenting at #ADA2019 or another conference and would like suggestions on how to share your content in addition to your poster or presentation, check out these tips.) This year, I’m co-author on three posters and an oral presentation.

  • 1056-P in category 12-D Clinical Therapeutics/New Technology–Insulin Delivery Systems, Preliminary Characterization of Rhythmic Glucose Variability In Individuals With Type 1 Diabetes, co-authored by Dana Lewis and Azure Grant.
    • Come see us at the poster session, 12-1pm on Sunday! Dana & Azure will be presenting this poster.
  • 76-OR, In-Depth Review of Glycemic Control and Glycemic Variability in People with Type 1 Diabetes Using Open Source Artificial Pancreas Systems, co-authored by Andreas Melmer, Thomas Züger, Dana Lewis, Scott Leibrand, Christoph Stettler, and Markus Laimer.
    • Come hear our presentation in room S-157 (South, Upper Mezzanine Level), 2:15-2:30 pm on Saturday!
  • 117-LB, DIWHY: Factors Influencing Motivation, Barriers and Duration of DIY Artificial Pancreas System Use Among Real-World Users, co-authored by Katarina Braune, Shane O’Donnell, Bryan Cleal, Ingrid Willaing, Adrian Tappe, Dana Lewis, Bastian Hauck, Renza Scibilia, Elizabeth Rowley, Winne Ko, Geraldine Doyle, Tahar Kechadi, Timothy C. Skinner, Klemens Raille, and the OPEN consortium.
    • Come see us at the poster session, 12-1pm on Sunday! Scott will be presenting this poster.
  • 78-LB, Detailing the Lived Experiences of People with Diabetes Using Do-it-Yourself Artificial Pancreas Systems – Qualitative Analysis of Responses to Open-Ended Items in an International Survey, co-authored by Bryan Cleal, Shane O’Donnell, Katarina Braune, Dana Lewis, Timothy C. Skinner, Bastian Hauck, Klemens Raille, and the OPEN consortium.
    • Come see us at the poster session, 12-1pm on Sunday! Bryan Cleal will be presenting this poster.

See below for full written summaries and pictures from each poster and the oral presentation.

First up: the biological rhythms poster, formally known as 1056-P in category 12-D Clinical Therapeutics/New Technology–Insulin Delivery Systems, Preliminary Characterization of Rhythmic Glucose Variability In Individuals With Type 1 Diabetes!

Lewis_Grant_BiologicalRhythmsT1D_ADA2019

As mentioned in this DiabetesMine interview, Azure Grant & I were thrilled to find out that we have been awarded a JDRF grant to further this research and undertake the first longitudinal study to characterize biological rhythms in T1D, which could also be used to inform improvements and personalize closed loop systems. This poster is part of the preliminary research we did in order to submit for this grant.

There is also a Twitter thread for this poster:

Poster from #ADA2019

Background:

  • Human physiology, including blood glucose, exhibits rhythms at multiple timescales, including hours (ultradian, UR), the day (circadian, CR), and the ~28-day female ovulatory cycle (OR).
  • Individuals with T1D may suffer rhythmic disruption due not only to the loss of insulin, but to injection of insulin that does not mimic natural insulin rhythms, the presence of endocrine-timing disruptive medications, and sleep disruption.
  • However, rhythms at multiple timescales in glucose have not been mapped in a large population of T1D, and the extent to which glucose rhythms differ in temporal structure between T1D and non-T1D individuals is not known.

Data & Methods:

  • The initial data set used for this work leverages the OpenAPS Data Commons. (This data set is available for all researchers  – see www.OpenAPS.org/data-commons)
  • All data was processed in Matlab 2018b with code written by Azure Grant. Frequency decompositions using the continuous morlet wavelet transformation were created to assess change in rhythmic composition of normalized blood glucose data from 5 non-T1D individuals and anonymized, retrospective CGM data from 19 T1D individuals using a DIY closed loop APS. Wavelet algorithms were modified from code made available by Dr. Tanya Leise at Amherst College (see http://bit.ly/LeiseWaveletAnalysis)

Results:

  • Inter and Intra-Individual Variability of Glucose Ultradian and Circadian Rhythms is Greater in T1D
Figure_BiologicalRhythms_Lewis_Grant_ADA2019

Figure 1. Single individual blood glucose over ~ 1 year with A.) High daily rhythm stability and B.) Low daily rhythm stability. Low glucose is shown in blue, high glucose in orange.

Figure 2. T1D individuals (N=19) showed a wide range of rhythmic power at the circadian and long-period ultradian timescales compared to individuals without T1D (N=5).

A). Individuals’ CR and UR power, reflecting amplitude and stability of CRs, varies widely in T1D individuals compared to those without T1D. UR power was of longer periodicity (>= 6 h) in T1D, likely due to DIA effects, whereas UR power was most commonly in the 1-3 hour range in non-T1D individuals (*not shown).  B.) On average, both CR and UR power were significantly higher in T1D (p<.05, Kruskal Wallis). This is most likely due to the higher amplitude of glucose oscillation, shown in two individuals in C.

Conclusions:

  • This is the first longitudinal analysis of the structure and variability of multi-timescale biological rhythms in T1D, compared to non-T1D individuals.
  • Individuals with T1D show a wide range of circadian and ultradian rhythmic amplitudes and stabilities, resulting in higher average and more variable wavelet power than in a smaller sample of non-T1D individuals.
  • Ultradian rhythms of people with T1D are of longer periodicity than individuals without T1D. These analyses constitute the first pass of a subset of these data sets, and will be continued over the next year.

Future work:

  • JDRF has recently funded our exploration of the Tidepool Big Data Donation Project, the OpenAPS Data Commons, and a set of non-T1D control data in order to map biological rhythms of glucose/insulin.
  • We will use signal processing techniques to thoroughly characterize URs, CRs, and ORs in the glucose/insulin for T1D; evaluate if stably rhythmic timing of glucose is associated with improved outcomes (lower HBA1C); and ultimately evaluate if modulation of insulin delivery based on time of day or time of ovulatory cycle could lead to improved outcomes.
  • Mapping population heterogeneity of these rhythms in people with and without T1D will improve understanding of real-world rhythmicity, and may lead to non-linear algorithms for optimizing glucose in T1D.

Acknowledgements:

We thank the OpenAPS community for their generous donation of data, and JDRF for the grant award to further this work, beginning in July 2019.

Contact:

Feel free to contact us at Dana@OpenAPS.org or azuredominique@berkeley.edu.

Next up, 78-LB, Detailing the Lived Experiences of People with Diabetes Using Do-it-Yourself Artificial Pancreas Systems – Qualitative Analysis of Responses to Open-Ended Items in an International Survey, co-authored by Bryan Cleal, Shane O’Donnell, Katarina Braune, Dana Lewis, Timothy C. Skinner, Bastian Hauck, Klemens Raille, and the OPEN consortium.

78-LB_LivedExperiencesDIYAPS_OPEN_ADA2019

There is also a Twitter thread for this poster:

Poster from OPEN survey on lived experiences

Introduction

There is currently a wave of interest in Do-it-Yourself Artificial Pancreas Systems (DIYAPS), but knowledge about how the use of these systems impacts on the lives of those that build and use them remains limited. Until now, only a select few have been able to give voice to their experiences in a research context. In this study we present data that addresses this shortcoming, detailing the lived experiences of people using DIYAPS in an extensive and diverse way.

Methods

An online survey with 34 items was distributed to DIYAPS users recruited through the Facebook groups “Looped” (and regional sub-groups) and Twitter pages of the Diabetes Online Community (DOC). Participants were posed two open-ended questions in the survey, where personal DIYAPS stories were garnered; including knowledge acquisition, decision-making, support and emotional aspects in the initiation of DIYAPS, perceived changes in clinical and quality of life (QoL) outcomes after initiation and difficulties encountered in the process. All answers were analyzed using thematic content analysis.

Results

In total, 886 adults responded to the survey and there were a combined 656 responses to the two open-ended items. Knowledge of DIYAPS was primarily obtained via exposure to the communication fora that constitute the DOC. The DOC was also a primary source of practical and emotional support (QUOTES A). Dramatic improvements in clinical and QoL outcomes were consistently reported (QUOTES B). The emotional impact was overwhelmingly positive, with participants emphasizing that the persistent presence of diabetes in everyday life was markedly reduced (QUOTES C). Acquisition of the requisite devices to initiate DIYAPS was sometimes problematic and some people did find building the systems to be technically challenging (QUOTE D). Overcoming these challenges did, however, leave people with a sense of accomplishment and, in some cases, improved levels of understanding and engagement with diabetes management (QUOTE E).

QuotesA_OPEN_ADA2019 QuotesB_OPEN_ADA2019 QuotesC_OPEN_ADA2019 QuotesD_OPEN_ADA2019 QuotesE_OPEN_ADA2019

Conclusion

The extensive testimony from users of DIYAPS acquired in this study provides new insights regarding the contours of this evolving phenomenon, highlighting factors inspiring people to adopt such solutions and underlining the transformative impact effective closed-loop systems bring to bear on the everyday lives of people with diabetes. Although DIYAPS is not a viable solution for everyone with type 1 diabetes, there is much to learn from those who have taken this route, and the life-changing results they have achieved should inspire all with an interest in artificial pancreas technology to pursue and dream of a future where all people with type 1 diabetes can reap the benefits that it potentially provides.

Also, see this word cloud generated from 665 responses in the two open-ended questions in the survey:

Wordle_OPEN_ADA2019

Next up is 117-LB, DIWHY: Factors Influencing Motivation, Barriers and Duration of DIY Artificial Pancreas System Use Among Real-World Users, co-authored by Katarina Braune, Shane O’Donnell, Bryan Cleal, Ingrid Willaing, Adrian Tappe, Dana Lewis, Bastian Hauck, Renza Scibilia, Elizabeth Rowley, Winne Ko, Geraldine Doyle, Tahar Kechadi, Timothy C. Skinner, Klemens Raille, and the OPEN consortium.

DIWHY_117-LB_OPEN_ADA2019

There is also a Twitter thread for this poster:

DIWHY Poster at ADA2019

Background

Until recently, digital innovations in healthcare have typically followed a ‘top-down’ pathway, with manufacturers leading the design and production of technology-enabled solutions and patients involved only as users of the end-product. However, this is now being disrupted by the increasing influence and popularity of more ‘bottom-up’ and patient-led open source initiatives. A primary example is the growing movement of people with diabetes (PwD) who create their own “Do-it-Yourself” Artificial Pancreas Systems (DIY APS) through remote-control of medical devices employing an open source algorithm.

Objective

Little is known about why PwD leave traditional care pathways and turn to DIY technology. This study aims to examine the motivations of current DIYAPS users and their caregivers.

Research Design and Methods

An online survey with 34 items was distributed to DIYAPS users recruited through the Facebook groups “Looped” (and regional sub-groups) and Twitter pages of the “DOC” (Diabetes Online Community). Self-reported data was collected, managed and analyzed using the secure REDCap electronic data capture tools hosted at Charité – Universitaetsmedizin Berlin.

Results

1058 participants from 34 countries (81.3 % Europe, 14.7 % North America, 6.0 % Australia/WP, 3.1 % Asia, 0.1 % Africa), responded to the survey, of which the majority were adults (80.2 %) with type 1 diabetes (98.9 %) using a DIY APS themselves (43.0 % female, 56.8 % male, 0.3 % other) with a median age of 41 y and an average diabetes duration of 25.2y ±13.3. 19.8 % of the participants were parents and/or caregivers of children with type 1 diabetes (99.4 %) using a DIY APS (47.4 % female, 52.6 % male) with a median age of 10 y and an average diabetes duration of 5.1y ± 3.8. People used various DIYAPS (58.2 % AndroidAPS, 28.5 % Loop, 18.8 % OpenAPS, 5.7 % other) on average for a duration of 10.1 months ±17.6 and reported an overall HbA1c-improvement of -0.83 % (from 7.07 % ±1.07 to 6.24 % ±0.68 %) and an overall Time in Range improvement of +19.86 % (from 63.21 % ±16.27 to 83.07 % ±10.11). Participants indicated that DIY APS use required them to pay out-of-pocket costs in addition to their standard healthcare expenses with an average amount of 712 USD spent per year.

Primary motivations for building a DIYAPS were to improve the overall glycaemic control, reduce acute and long-term complication risk, increase life expectancy and to put diabetes on ‘auto-pilot’ and interact less frequently with the system. Lack of commercially available closed loop systems and improvement of sleep quality was a motivation for some. For caregivers, improvement of their own sleep quality was the leading motivation. For adults, curiosity (medical or technical interest) had a higher impact on their motivation compared to caregivers. Some people feel that commercial systems do not suit their individual needs and prefer to use a customizable system, which is only available to them as a DIY solution. Other reasons, like costs of commercially available systems and unachieved therapy goals played a subordinate role. Lack of medical or psychosocial support was less likely to be motivating factors for both groups.

Figure_OPEN_DIWHY_ADA2019

Conclusions

Our findings suggest that people using Do-it-Yourself Artificial Pancreas systems and their caregivers are highly motivated to improve their/their children’s diabetes management through the use of this novel technology. They are also able to access and afford the tools needed to use these systems. Currently approved and available commercial therapy options may not be sufficiently flexible or customizable enough to fulfill their individual needs. As part of the project “OPEN”, the results of the DIWHY survey may contribute to a better understanding of the unmet needs of PwD and current challenges to uptake, which will, in turn, facilitate dialogue and collaboration to strengthen the involvement of open source approaches in healthcare.

This is a written version of the oral presentation, In-Depth Review of Glycemic Control and Glycemic Variability in People with Type 1 Diabetes Using Open Source Artificial Pancreas Systems, co-authored by Andreas Melmer, Thomas Züger, Dana Lewis, Scott Leibrand, Christoph Stettler, and Markus Laimer.

APSComponents_Melmer_ADA2019

Artificial Pancreas Systems (APS) now exist, leveraging a CGM sensor, pump, and control algorithm. Faster insulin can play a role, too.  Traditionally, APS is developed by commercial industry, tested by clinicians, regulated, and then patients can access it. However, DIYAPS is designed by patients for individual use.

There are now multiple different kinds of DIYAPS systems in use: #OpenAPS, Loop, and AndroidAPS. There are differences in hardware, pump, and software configurations. The main algorithm for OpenAPS is also used in AndroidAPS.  DIYAPS can work offline; and also leverage the cloud for accessing or displaying data, including for remote monitoring.OnlineOffline_Melmer_ADA2019

This study analyzed data from the OpenAPS Data Commons (see more here). At the time this data set was used, there were n=80 anonymized data donors from the #OpenAPS community, with a combined 53+ years worth of CGM data.

TIR_PostLooping_Melmer_ADA2019Looking at results for #OpenAPS data donors post-looping initiation, CV was 35.5±5.9, while eA1c was 6.4±0.7. TIR (3.9-10mmol/L) was 77.5%. Time spent >10 was 18.2%; time <3.9 was 4.3%.

SubcohortData_Melmer_ADA2019We selected a subcohort of n=34 who had data available from before DIY closed looping initiation (6.5 years combined of CGM records), as well as data from after (12.5 years of CGM records).

For these next set of graphs, blue is BEFORE initiation (when just on a traditional pump); red is AFTER, when they were using DIYAPS.

TIR_PrePost_Melmer_ADA2019Time in a range significantly increased for both wider (3.9-10 mmol/L) and tighter (3.9-7.8 mmol/L) ranges.

TOR_PrePost_Melmer_ADA2019Time spent out of range decreased. % time spent >10 mmol/L decreased -8.3±8.6 (p<0.001); >13 mmol/L decreased -3.3±5.0 (p<0.001). Change in % time spent <3.9 mmol/L (-1.1±3.8 (p=0.153)), and <3.0 mmol/L (-0.7±2.2 (p=0.017)) was not significant.

We also analyzed daytime and nightime (the above was reflecting all 24hr combined; these graphs shows the increase in TIR and decrease in time out of range for both day and night).

TIR_TOR_DayAndNight_Melmer_ADA2019

Hypoglemic_event_reduction_Melmer_ADA2019There were less CGM records in the hypoglycemic range after initiating DIYAPS.

Conclusion: this was a descriptive study analyzing available CGM data from  #OpenAPS Data Commons. This study shows OpenAPS has potential to support glycemic control. However, DIYAPS are currently not regulated/approved technology. Further research is recommended.

Conclusion_Melmer_ADA2019

(Note: a version of this study has been submitted and accepted for publication in the Journal of Diabetes. Obesity, and Metabolism.)